Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The naming approach proposed is a departure from well-established scientific naming principles
October 30, 2015
By: Kristin Brooks
Managing Editor, Contract Pharma
The United States Pharmacopeial Convention (USP) has commented on the FDA draft guidance, “Nonproprietary Naming of Biological Products: Guidance for Industry”, which describes FDA’s proposal that all biologics bear a nonproprietary name that includes a manufacturer-specific FDA-designated suffix. “We understand the naming approach for biologics in the Draft Guidance reflects FDA’s interest in preventing inadvertent substitution of and facilitating pharmacovigilance for biological products,” said Jaap Venema, Ph.D., executive vice president and chief science officer of USP. “At the same time, USP believes it is critically important to maintain a uniform and scientifically-based approach that does not create unintended risks for patients and practitioners, and encourages FDA to consider alternative solutions to reach its goals.” Throughout its history, USP has helped ensure medicines are of high-quality, safe and effective through its legally-recognized role in setting scientifically-based public standards for identity, purity, quality and strength, as well as packaging and labeling. As part of USP’s legally mandated role, the organization is part of a well-established drug naming system, which includes the naming of biologics. USP’s comments to the FDA’s draft guidance highlights the following key concepts: (1) USP has a long history of setting quality standards for biologic drug substances and products; (2) the existing scientifically-based nonproprietary naming system for biologics and other drugs has served patients and practitioners well for over a century; (3) the naming approach proposed in the Draft Guidance represents a departure from well-established scientific naming principles and could have unintended negative consequences; (4) while USP shares FDA’s goal of improving safe medication use, USP encourages FDA to consider alternative solutions to achieve this goal.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !